Fenton Mary Kay
- SEC CIK
- 0001378589
In the past year, 1 open-market sale filing worth $59.9K and no purchases.
Current role at each company
- CGEM Cullinan Therapeutics, Inc.Chief Financial Officeras of Jul 2, 2026
- TRML Tourmaline Bio, Inc.Chief Financial Officeras of Jul 6, 2023
- ONCR Oncorus, Inc.Directoras of Jun 24, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $59.9K
- 1 filing
- Net
- −$59.9K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Fenton Mary Kay as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
CGEM Cullinan Therapeutics, Inc.
Chief Financial Officer1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2026 (view filing) | Feb 20 | 3 days | Fenton Mary KayChief Financial Officer | SSale | −4.40K | $13.62 | −$59.9K | −3.4%126.4K after |